Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077194 · ClinicalTrials.gov registry record · Phase 2
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00077194: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00077194 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077194, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase II trial is studying how well FR901228 works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077194
The ClinicalTrials.gov registry entry for NCT00077194 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which romidepsin is the first listed.
NCT00077194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077194 about?
NCT00077194 is a clinical study titled "FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". This phase II trial is studying how well FR901228 works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00077194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2004-01.
What interventions are being tested in trial NCT00077194?
The interventions under investigation include: romidepsin (DRUG).
Who is sponsoring clinical trial NCT00077194?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.